ERBB2 and breast ductal adenocarcinoma: These results are consistent with previous findings that indicated a role of HER-2/neu in initiation rather than in progression of ductal carcinomas and suggested that this biomarker decreases as individual tumor cells evolve from in situ to increasingly invasive lesions [32].